Sarah Spencer
Investor Relations Contact chez VOR BIOPHARMA INC.
Profil
Sarah Spencer is currently the Head-Investor & Media at Vor Biopharma, Inc. She previously worked as a Media Relations Contact at GSK Plc and as the Vice President-Corporate Communications at Astellas Gene Therapies, Inc. from 2019 to 2021.
Ms. Spencer obtained an undergraduate degree from the State University of New York at Buffalo.
Postes actifs de Sarah Spencer
| Sociétés | Poste | Début |
|---|---|---|
| VOR BIOPHARMA INC. | Investor Relations Contact | - |
Anciens postes connus de Sarah Spencer
| Sociétés | Poste | Fin |
|---|---|---|
| AUDENTES THERAPEUTICS, INC. | Public Communications Contact | 01/04/2021 |
| GSK PLC | Public Communications Contact | - |
Formation de Sarah Spencer
| State University of New York at Buffalo | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GSK PLC | Health Technology |
| VOR BIOPHARMA INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Astellas Gene Therapies, Inc.
 Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |